Navigation Links
Genetic mutation found in peripheral artery disease
Date:2/22/2008

The finding, appearing online in the journal Circulation, is the first to document a genetic mutation linked to PAD. Although the work was done in mice, researchers say it is likely to give them new insight into how PAD develops and progresses in humans.

Dr. Brian Annex, professor of medicine and director of vascular medicine at Duke, says the study stemmed directly from his clinical experience. Over and over, Id see two patients show up at the same time. They would be the same sex, same age, have identical risk factors and have similar blockages in their arteries. One of them would experience very slow progression of the disease, while the other would face limb loss or death within six months. I just knew there just had to be a genetic basis for it.

Peripheral arterial disease occurs when major arteries in the legs become clogged with plaque, a fatty build-up thats similar to the deposits in coronary arteries that can lead to a heart attack. Symptoms range from leg pain brought on by walking that goes away with rest thats the more benign form of the disease to a more serious form, marked by continuous pain and sores and ulcers on the legs that often lead to amputation.

Annex says the mild form rarely progresses into the more severe form. In reality, we may be looking at two types of diseases, although weve always thought of PAD as one.

Annex had the perfect participants for the study right at his fingertips: two strains of mice with surgically-induced blocked blood flow that mimicked human response to PAD. One strain recovered well, showing restored blood flow and little tissue death; the other had greater tissue loss and poor recovery of normal blood flow.

In collaboration with Dr. Douglas Marchuk, a professor of molecular genetics and microbiology at Duke, researchers crossbred the two strains and eventually isolated a mouse that enabled them to identify a relatively small region on chromosome 7 that app
'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...-USNewswire/ -- The Custom Briefings,network of Bu...e Endocrine,Daily Briefing, produced exclusively f...y., Endocrine Daily Briefing is emailed Monday th...ers, medical professionals engaged in the,fight ag...Endocrine Daily,Briefing joins a network of medica...
(Date:8/29/2008)...USNewswire/ -- The following is a,statement by Mat...e Kids:, For the second time in a month, Philip M...p and promotion of a concert in a developing count...engaging in cigarette,marketing that appeals to ch...as been forced to withdraw from,an August 30 reuni...
(Date:8/29/2008)...swire-FirstCall/ -- InterMune, Inc.,(Nasdaq: ITMN... CEO and,President of InterMune, will present at t... Boston on September 4, 2008 at 10:55 a.m. EDT., ..., investors and other,interested parties may log o...rporate website at http://www.intermune.com . The...
(Date:8/29/2008)...re Than 30 European Countries, HONOLULU, Aug. 29 ...y,that it has successfully completed the intensive...evice Directive (for most European Union countries...or Conformite Europeene Mark,-- for the LifeBed(TM...atient safety reach to include more than 30 countr...
Breaking Medicine News(10 mins):Health News:Custom Briefings Announces Launch of Endocrine Daily Briefing 2Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 2Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 3Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 4
...ng too many high-fat meals will clog arteries and ...ews that even a single high-fat meal can quickly s...ate pumping up of blood pressure levels could prov...rough which high fat meals produce heart disease o...
...ished in PLoS Medicine journal by Cambridge rese...t which a woman first menstruates.// These are he...eight and risk of obesity in later life. Research...ouncil and University of Cambridge, led by Dr Ken ...
...omen who drink more two bottles of wine over the w...breast cancer. // The study reported in the Europ...p of 17,647 nurses who drank 22-27 drinks a week c...e drinks, the risk of breast cancer was two times ...
...ble searing feeling in your stomach and chest, is ...According to researchers, modern day life with its...r sleep necessitates the purchase of fast foods an... root cause of the problem, they say. A study co...
Other Medicine News:Health News:A Single High Fat Meal Could Boost Blood Pressures 2Health News:Women Binge- Drinkers Warned Of Possible Link To Breast Cancer 2Health News:Heartburn Shadowing Modern India 2
(Date:8/27/2008)...ght in Parts of Bucks, Delaware, Montgomery,Phila...swire-USNewswire/ -- After encouraging,results fol...epartment of,Environmental Protection will continu...gainst the mosquito-borne West Nile virus., Targe... 8 p.m. and,midnight in portions of Bucks, Delawar...
(Date:8/27/2008)...CADE, melphalan and prednisone arm demonstrated a,...cent complete response -, CAMBRIDGE, Mass., Aug. ... Company today announced the publication of result...A(1) trial in this week,s edition of the,New Engla...ficant survival,benefit and a 30 percent complete ...
(Date:8/27/2008)...st 27 /-, - Oralair(R) Gra...harmacodynamic Study Conducted in an Allergen Chal...ghly positive results of a new study,conducted in ...n Oralair(R) Grasses included 86 adult patients ex...atment durations: 1 week, 1 month,2 and 4 months ...
(Date:8/27/2008)...a, from BLISS-52 trial, expected by mid-2009 - - ... by fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewsw...daq: HGSI ) today announced it has completed enro...of two pivotal Phase 3,randomized clinical trials ...tive systemic lupus erythematosus (SLE). Belimumab...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 1Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 2Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 3Smokers Cost Medicaid System Nearly 2410 Billion 7170 1Smokers Cost Medicaid System Nearly 2410 Billion 7170 2Smokers Cost Medicaid System Nearly 2410 Billion 7170 3Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 1Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 2Meniscal damage and the development of persistent knee pain 7168 1Meniscal damage and the development of persistent knee pain 7168 2Meniscal damage and the development of persistent knee pain 7168 3
...ults Indicate Bioequivalent Pharmacokinetics With ...X-514, SAN DIEGO, April 25, 2007 /PRNewswire-First...rmaceutical research and,development company focus...es for the treatment of cancer and infectious dise...nical pharmacokinetic,testing of ANX-514 (docetaxe...
...SEL, Switzerland, April 25, 2007 - Basilea Pharmac...udy results showing that,patients with severe chro... alitretinoin. In two previous randomized clinical... treating severe,chronic hand eczema in patients r...l demonstrated that patients responsive to initial...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
The new PERIMOUNT Magna heart valve (bioprosthesis), with its true supra-annular design, offers optimal hemodynamics and flow characteristics for treatment of aortic heart valve disease.
... in high performance ultrasound design provides un...Echocardiography imaging requires superior spatial...er performance. The Terason Echo Ultrasound System...ecture, delivers a compact imaging platform withou...
...mplified In-office. Information. In real time. The...definitive indications of elevated vaginal fluid p...The innovative format is easy to use and delivers ...rub a swab containing unprocessed vaginal fluid ac...
For the quantitative determination of human MMP-9/NGAL Complex concentrations in cell culture supernates, serum,plasma, urine and saliva.
Medicine Products: